BioVaxys Technology Corp. (BVAXF)
PNK · Healthcare · Biotechnology
Closing price as of 2026-09-10 · Source: TEK2day Finance
Key Metrics
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
Quarterly Financials
| Metric | 2024-10-31 | 2025-01-31 | 2025-04-30 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.5M) | (1.2M) | (1.3M) |
| Net Income | (2.7M) | (1.1M) | (1.3M) |
| Diluted EPS | N/A | $0.00 | $0.00 |
Annual Financials
| Metric | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.4M) | (4.1M) | (6.5M) | (3.3M) |
| Net Income | (6.5M) | (11.7M) | (7.7M) | (4.0M) |
| Diluted EPS | $-0.80 | $-1.20 | $-0.60 | $-0.20 |